Bioorganic & Medicinal Chemistry Letters
Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinoline-2(1<em>H</em>)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor
Publication date: Available online 9 March 2023Source: Bioorganic & Medicinal Chemistry LettersAuthor(s): Jay Chauhan, Makoto Yoshioka, Sarah Pogash, Jeffrey W. Strovel, Steven Fletcher